News

CLOUD DX Renews 11 Customer Contracts Valued at $1.25 Million

High 2024 contract renewal rate demonstrates continued client satisfaction.News in SummaryFrom January 1, 2024 to March 26, 2024 Cloud DX…

2 years ago

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a…

2 years ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults

TORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

2 years ago

BlueSleep Announces Care Partnership With Eastern Dental

New Collaboration Aims to Expand Access to High-Quality Sleep Medicine to Eastern Dental's Patients in New JerseyNEW YORK, NY /…

2 years ago

Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study

SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased…

2 years ago

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing…

2 years ago

Theralase(R) Release’s 4Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

2 years ago

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpointsExpects two more Phase 3…

2 years ago

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

2 years ago

Årsregnskab 2023 – Et begivenhedsrigt år for selskabet

2023 var et begivenhedsrigt år for selskabet, hvor den primære fokus i første halvår bestod i at overlevere driften af…

2 years ago